Compare LTC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | TLX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1994 | N/A |
| Metric | LTC | TLX |
|---|---|---|
| Price | $38.38 | $8.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $39.00 | $21.13 |
| AVG Volume (30 Days) | ★ 337.3K | 296.1K |
| Earning Date | 05-04-2026 | 02-19-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | ★ 23.53 | N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $262,854,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.24 | N/A |
| P/E Ratio | ★ $15.35 | $150.33 |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $31.70 | $6.28 |
| 52 Week High | $40.80 | $19.93 |
| Indicator | LTC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 64.40 |
| Support Level | $34.13 | $7.72 |
| Resistance Level | $40.05 | $8.45 |
| Average True Range (ATR) | 0.71 | 0.23 |
| MACD | -0.17 | 0.14 |
| Stochastic Oscillator | 22.64 | 87.76 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.